---
title: Olmesartan Medoxomil
description: >-
  - Olmesartan Medoxomil is primarily prescribed for the treatment of
  **hypertension** (high blood pressure) in adults and children aged 6-17 years.
  - **Pharmacological Classification:** Angiotensin II Receptor Blocker (ARB) -
  **Mechanism of Action:** Olmesartan Medoxomil blocks the action of angio...
is_banned: false
lastModified: '2025-09-22T17:21:53.766Z'
faqs:
  - q: >-
      What is the recommended dosage for Olmesartan Medoxomil?**

      **A:** Adults: Initial dose is 20 mg once daily, which may be increased to
      40 mg daily if needed. Children (6-17 years): Initial dose is 10 mg once
      daily for patients 20 to <35 kg, or 20 mg once daily for those ≥35 kg,
      which may be increased to a maximum of 20 mg or 40 mg daily, respectively.
    a: >-
      A:** Adults: Initial dose is 20 mg once daily, which may be increased to
      40 mg daily if needed. Children (6-17 years): Initial dose is 10 mg once
      daily for patients 20 to <35 kg, or 20 mg once daily for those ≥35 kg,
      which may be increased to a maximum of 20 mg or 40 mg daily, respectively.
  - q: >-
      What are the common side effects of Olmesartan Medoxomil?**

      **A:** Common side effects include dizziness, headache, fatigue, and upper
      respiratory tract infections.
    a: >-
      A:** Common side effects include dizziness, headache, fatigue, and upper
      respiratory tract infections.
  - q: >-
      Can Olmesartan Medoxomil be used in pregnancy?**

      **A:**  Olmesartan Medoxomil is contraindicated during the second and
      third trimesters of pregnancy due to the risk of fetal harm.  Its use in
      the first trimester should be carefully considered.
    a: >-
      A:**  Olmesartan Medoxomil is contraindicated during the second and third
      trimesters of pregnancy due to the risk of fetal harm.  Its use in the
      first trimester should be carefully considered.
  - q: >-
      How does Olmesartan Medoxomil interact with other antihypertensive
      medications?**

      **A:**  Olmesartan Medoxomil can have additive hypotensive effects when
      used with other antihypertensive drugs. Dosage adjustments may be
      necessary.
    a: >-
      A:**  Olmesartan Medoxomil can have additive hypotensive effects when used
      with other antihypertensive drugs. Dosage adjustments may be necessary.
  - q: >-
      What should be monitored in patients taking Olmesartan Medoxomil?**

      **A:**  Blood pressure, renal function (especially serum creatinine and
      potassium levels), should be monitored regularly.
    a: >-
      A:**  Blood pressure, renal function (especially serum creatinine and
      potassium levels), should be monitored regularly.
  - q: >-
      Is Olmesartan Medoxomil safe to use in patients with renal impairment?**

      **A:** It can be used in patients with mild to moderate renal impairment,
      with a maximum dose of 20mg daily. It is not recommended in patients with
      severe renal impairment.
    a: >-
      A:** It can be used in patients with mild to moderate renal impairment,
      with a maximum dose of 20mg daily. It is not recommended in patients with
      severe renal impairment.
  - q: >-
      Can Olmesartan Medoxomil be used in children?**

      **A:** It is approved for use in children aged 6-17 years for the
      treatment of hypertension.
    a: >-
      A:** It is approved for use in children aged 6-17 years for the treatment
      of hypertension.
  - q: >-
      What is the mechanism of action of Olmesartan Medoxomil?**

      **A:**  It is an angiotensin II receptor blocker (ARB) that blocks the
      action of angiotensin II, leading to vasodilation and a decrease in blood
      pressure.
    a: >-
      A:**  It is an angiotensin II receptor blocker (ARB) that blocks the
      action of angiotensin II, leading to vasodilation and a decrease in blood
      pressure.
  - q: >-
      What should I do if my patient experiences angioedema while taking
      Olmesartan Medoxomil?**

      **A:** Angioedema is a serious side effect and requires immediate medical
      attention. Discontinue the medication and provide appropriate supportive
      care.
    a: >-
      A:** Angioedema is a serious side effect and requires immediate medical
      attention. Discontinue the medication and provide appropriate supportive
      care.
---
## **Usage**

- Olmesartan Medoxomil is primarily prescribed for the treatment of **hypertension** (high blood pressure) in adults and children aged 6-17 years.
- **Pharmacological Classification:** Angiotensin II Receptor Blocker (ARB)
- **Mechanism of Action:** Olmesartan Medoxomil blocks the action of angiotensin II, a hormone that causes blood vessels to constrict. By blocking angiotensin II receptors, Olmesartan Medoxomil causes vasodilation, lowering blood pressure.


## **Alternate Names**

- International variations may exist.
- **Brand Names:** Benicar, Olmetec, and others (various generic versions are also available).

## **How It Works**

- **Pharmacodynamics:** Olmesartan Medoxomil lowers blood pressure by blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and other tissues. This blockade inhibits the vasoconstricting and aldosterone-secreting effects of angiotensin II, resulting in decreased blood pressure.
- **Pharmacokinetics:**  Olmesartan Medoxomil is a prodrug that is rapidly converted to its active metabolite, olmesartan, during absorption from the gastrointestinal tract. It is moderately absorbed, with peak plasma concentrations reached within 1-2 hours. Olmesartan is highly bound to plasma proteins. It is primarily eliminated via the biliary route (feces) with a small fraction excreted unchanged in urine. The elimination half-life is approximately 13 hours.
- **Mode of Action:** Olmesartan competitively blocks the binding of angiotensin II to the type 1 angiotensin II receptor (AT1 receptor).
- **Receptor Binding:**  Selectively binds to the AT1 receptor.
- **Elimination Pathways:** Primarily biliary excretion (feces), with a small amount of renal excretion (urine).

## **Dosage**

### **Standard Dosage**

#### **Adults:**
- Initial dose: 20 mg orally once daily.
- Maintenance dose: May increase to 40 mg once daily if needed after 2 weeks. Doses above 40mg daily are not recommended.
- For patients with possible intravascular volume depletion, consider a lower starting dose of 10mg daily.


#### **Children (6-17 years):**
-  Initial dose: 10 mg orally once daily for patients weighing 20 to <35 kg, or 20 mg orally once daily for patients weighing ≥35 kg.
- Maintenance Dose: May be increased to a maximum of 20 mg once daily (for patients <35 kg) or 40 mg once daily (for patients ≥35 kg) if needed after 2 weeks.
- Children younger than 6 years of age: Safety and efficacy not established.


#### **Special Cases:**
- **Elderly Patients:** No initial dose adjustment is generally required.  Close monitoring of blood pressure is recommended, particularly if titrating to the maximum dose.
- **Patients with Renal Impairment:** For mild to moderate renal impairment (creatinine clearance 20-60 mL/min): Maximum dose is 20 mg daily. Not recommended for severe renal impairment (creatinine clearance <20 mL/min).
- **Patients with Hepatic Dysfunction:**  For mild to moderate hepatic impairment: No initial dose adjustment required, though close monitoring of blood pressure is advised.  For moderate impairment, a maximum dose of 20 mg daily is recommended. There is no experience with olmesartan medoxomil in patients with severe hepatic impairment.
- **Patients with Comorbid Conditions:** Use with caution and monitor closely in patients with conditions such as heart failure or diabetes.


### **Clinical Use Cases**
Olmesartan Medoxomil is not typically indicated for acute clinical situations like intubation, surgical procedures, mechanical ventilation, ICU use, or emergency situations. It is primarily used for chronic blood pressure management. 

### **Dosage Adjustments:**
- Adjust dosage based on patient response and tolerability.
- Consider renal and hepatic function, as well as other comorbid conditions, when adjusting dosage.


## **Side Effects**

### **Common Side Effects:**
- Dizziness
- Headache
- Fatigue
- Upper respiratory infections
- Back pain
- Bronchitis
- Diarrhea


### **Rare but Serious Side Effects:**
- Angioedema (swelling of face, lips, tongue, or throat)
- Renal failure
- Hyperkalemia (high potassium levels)
- Hypotension (low blood pressure)


### **Long-Term Effects:**
- Potential long-term effects include renal dysfunction and cardiovascular complications if hypertension remains uncontrolled.


### **Adverse Drug Reactions (ADR):**
- Angioedema requires immediate medical attention.
- Signs of renal failure or hyperkalemia necessitate prompt intervention.


## **Contraindications:**
- Hypersensitivity to olmesartan medoxomil.
- Pregnancy (second and third trimesters).
- Concurrent use with aliskiren in patients with diabetes.
- Bilateral renal artery stenosis.


## **Drug Interactions:**
- Other antihypertensive medications (additive hypotensive effects).
- Potassium supplements or potassium-sparing diuretics (increased risk of hyperkalemia).
- NSAIDs (may reduce antihypertensive effect and increase risk of renal impairment).
- Lithium (increased lithium levels).


## **Pregnancy and Breastfeeding:**
- **Pregnancy Safety Category:**  D (second and third trimesters); C (first trimester). Not recommended during pregnancy due to potential risk of fetal harm.
- **Breastfeeding:**  Not known if olmesartan is excreted in human milk.  Use with caution.



## **Drug Profile Summary**
- **Mechanism of Action:** Angiotensin II receptor blocker (ARB).
- **Side Effects:** Dizziness, headache, fatigue, upper respiratory infections, back pain, bronchitis, diarrhea. Rarely: angioedema, renal failure, hyperkalemia, hypotension.
- **Contraindications:** Hypersensitivity, pregnancy, concurrent use with aliskiren in diabetic patients.
- **Drug Interactions:** Other antihypertensives, potassium supplements, NSAIDs, lithium.
- **Pregnancy & Breastfeeding:**  Contraindicated in second and third trimesters of pregnancy; use with caution during breastfeeding.
- **Dosage:** Adults: 20-40mg once daily; Children 6-17 years: 10-40 mg based on weight, once daily.
- **Monitoring Parameters:** Blood pressure, renal function, potassium levels.


## **Popular Combinations:**
- Olmesartan Medoxomil/Hydrochlorothiazide: This combination provides synergistic antihypertensive effects by combining an ARB with a diuretic.


## **Precautions**
- Monitor renal function, especially in patients with pre-existing renal impairment.
- Monitor potassium levels, especially in patients taking potassium supplements or potassium-sparing diuretics.
- Use with caution in patients with hepatic impairment.
- Avoid in pregnancy, especially during the second and third trimesters.


## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Olmesartan Medoxomil?**
**A:** Adults: Initial dose is 20 mg once daily, which may be increased to 40 mg daily if needed. Children (6-17 years): Initial dose is 10 mg once daily for patients 20 to <35 kg, or 20 mg once daily for those ≥35 kg, which may be increased to a maximum of 20 mg or 40 mg daily, respectively.


### **Q2: What are the common side effects of Olmesartan Medoxomil?**
**A:** Common side effects include dizziness, headache, fatigue, and upper respiratory tract infections.

### **Q3: Can Olmesartan Medoxomil be used in pregnancy?**
**A:**  Olmesartan Medoxomil is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm.  Its use in the first trimester should be carefully considered.


### **Q4: How does Olmesartan Medoxomil interact with other antihypertensive medications?**
**A:**  Olmesartan Medoxomil can have additive hypotensive effects when used with other antihypertensive drugs. Dosage adjustments may be necessary.


### **Q5: What should be monitored in patients taking Olmesartan Medoxomil?**
**A:**  Blood pressure, renal function (especially serum creatinine and potassium levels), should be monitored regularly.

### **Q6:  Is Olmesartan Medoxomil safe to use in patients with renal impairment?**
**A:** It can be used in patients with mild to moderate renal impairment, with a maximum dose of 20mg daily. It is not recommended in patients with severe renal impairment.

### **Q7: Can Olmesartan Medoxomil be used in children?**
**A:** It is approved for use in children aged 6-17 years for the treatment of hypertension.


### **Q8: What is the mechanism of action of Olmesartan Medoxomil?**
**A:**  It is an angiotensin II receptor blocker (ARB) that blocks the action of angiotensin II, leading to vasodilation and a decrease in blood pressure.



### **Q9: What should I do if my patient experiences angioedema while taking Olmesartan Medoxomil?**
**A:** Angioedema is a serious side effect and requires immediate medical attention. Discontinue the medication and provide appropriate supportive care.



